|
±è¹üÁØ ±³¼ö
|
±èµ¿ÇÏ Àü°øÀÇ
|
Á߾Ӵ뺴¿ø ±è¹üÁØ ±³¼ö¿Í ±èµ¿ÇÏ Àü°øÀÇÀÇ ³í¹®ÀÌ »ý¹°Çבּ¸Á¤º¸¼¾ÅÍ(BRIC. Biological Research Information Center) ‘Çѱ¹À» ºû³½ »ç¶÷µé’¿¡ µîÀçµÆ´Ù.
Áß¾Ó´ëÇб³º´¿ø(¿øÀå ±è¼º´ö)¿¡ µû¸£¸é ±è ±³¼ö¿Í ±è Àü°øÀÇ´Â Áö³ÇØ¿µ±¹ÇǺΰúÇÐȸ °ø½ÄÇмúÁö ‘Clinical and Experimental Dermatology’¿¡ ‘³Ä¡¼º ¾ÆÅäÇÇÇǺο°¿¡¼ Ç× ¸é¿ª±Û·ÎºÒ¸° E Á¦Á¦(¿À¸»¸®ÁÖ¸¿, Omalizumab)ÀÇ Ä¡·á È¿°ú(Anti-immunoglobulin E in the treatment of refractory atopic dermatitis)’¶õ Á¦¸ñÀÇ ³í¹®À» ¹ßÇ¥ÇÞ´Ù.
ÀÌ ³í¹®ÀÌ ¼¼°è ÀÇÇаú »ý¹°ÇÐ ºÐ¾ß »óÀ§ 2%ÀÇ Áß¿ä ³í¹®À» ÃßõÇÏ´Â 'õ ¸íÀÇ ³í¹® °ËÅäÀÚ(Faculty of 1000)'µé·ÎºÎÅÍ Ãßõ¹Þ¾Æ Æ÷Ç×°ø´ë »ý¹°Çבּ¸Á¤º¸¼¾ÅÍ(BRIC)°¡ ¿î¿µÇÏ´Â 'Çѱ¹À» ºû³»´Â »ç¶÷µé'¿¡ ‘Ãßõ ³í¹®’À¸·Î ¼Ò°³µÆ´Ù.
ÀÌ ³í¹®Àº ³Ä¡¼º ¾ÆÅäÇÇÇǺο° ȯÀÚ Áß ¸é¿ª±Û·ÎºÒ¸° E ¼öÄ¡°¡ Áõ°¡µÈ ȯÀÚ¿¡°Ô ¿À¸»¸®ÁÖ¸¿ÀÌ È¿°úÀûÀÎ Ä¡·á¸¦ º¸ÀÌ´Â °ÍÀ» ÀÔÁõ, ÀÓ»ó È°¿ë¿¡ µµ¿òÀÌ µÉ °ÍÀ̶ó´Â Æò°¡¸¦ ¹Þ°í ÀÖ´Ù.
ÇÑÆí, »ý¹°Çבּ¸Á¤º¸¼¾ÅÍ(BRIC)°¡ ¿î¿µÇÏ´Â 'Çѱ¹À» ºû³»´Â »ç¶÷µé'Àº ÇØ¿Ü ÁÖ¿ä ÇмúÁö¿¡ Åõ°íÇÑ Çѱ¹ °úÇÐÀÚµéÀÇ ³í¹®À» ¼Ò°³ÇÔÀ¸·Î½á ¿ì¼öÇÑ ³í¹®µéÀ» ±¹³» ¿¬±¸Àڵ鿡°Ô ¾Ë¸®·Á´Â ÃëÁö¿¡¼ ¸¸µé¾îÁ³´Ù.
'Çѱ¹À» ºû³»´Â »ç¶÷µé'Àº °ÔÀçÁ¶°ÇÀ¸·Î ‘»óÀ§ÇÇÀοë³í¹®’, ‘Ãßõ³í¹®’ Ƚ¼ö°¡ ³ôÀº ³í¹® µîÀ» ¼Ò°³ÇÏ´Â ±âÁØÀ» ¸¶·ÃÇØ ³õ°í ÀÖ´Ù.
ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.